Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor
Br J Haematol
.
2020 Jan;188(1):187-191.
doi: 10.1111/bjh.16265.
Authors
Åsa Derolf
1
2
,
Gunnar Juliusson
3
,
Lina Benson
4
,
Yngvar Fløisand
5
,
Vladimir Lazarevic
3
,
Petar Antunovic
6
,
Lars Möllgård
7
,
Sören Lehmann
8
,
Bertil Uggla
9
,
Anders Wahlin
10
,
Martin Höglund
8
,
Stefan Deneberg
1
2
Affiliations
1
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
2
Department of Internal Medicine, Karolinska Institutet, Stockholm, Sweden.
3
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
4
Epidemiology and Regional Oncologic Center in Stockholm, Stockholm, Sweden.
5
Department of Hematology, Oslo University Hospital, Oslo, Sweden.
6
Department of Hematology, Linköping University Hospital, Linköping, Sweden.
7
Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
8
Department of Medical Sciences, Unit of Haematology, Uppsala University, Uppsala, Sweden.
9
Department of Medicine, School of Health and Medical Sciences, Örebro University Hospital, Örebro, Sweden.
10
Department of Radiation Sciences, Umeå University, Umeå, Sweden.
PMID:
31863470
DOI:
10.1111/bjh.16265
No abstract available
Publication types
Letter
MeSH terms
Aged
Disease-Free Survival
Female
Humans
Leukemia, Myeloid, Acute / mortality*
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Registries*
Retrospective Studies
Risk Factors
Survival Rate
Sweden / epidemiology